A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Novartis
Pfizer
Erasca, Inc.
Incyte Corporation
Allist Pharmaceuticals, Inc.
Pfizer
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Genentech, Inc.
University of Wisconsin, Madison
Alliance for Clinical Trials in Oncology
Rabin Medical Center
Gruppo Oncologico del Nord-Ovest
M.D. Anderson Cancer Center
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center
Pfizer
Sun Yat-sen University
University of Campania Luigi Vanvitelli
Mirati Therapeutics Inc.
University of Colorado, Denver
Academic and Community Cancer Research United
Ono Pharmaceutical Co., Ltd.
RenJi Hospital